Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone resorption; Osteoporosis
- Focus Therapeutic Use
- 29 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jan 2011 New source identified and integrated (ClinicalTrials.gov).
- 21 Jan 2011 Lead trial centre identified as reported by ClinicalTrials.gov.